Ursolic acid inhibits glioblastoma through suppressing TGFβ-mediated epithelial-mesenchymal transition (EMT) and angiogenesis

Hei, Bo; Liu, Ru-en; Li, Meihua

doi:10.1016/j.heliyon.2024.e27722

Cited by 3 publications

(1 citation statement)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent research indicates that ursolic acid can inhibit the TGF‐β‐induced EMT in glioblastoma. 239 Besides, targeting the EGFR involved in EMT with the EGFR inhibitor gefitinib can inhibit the tamoxifen resistance, invasion and migration via downregulating Snail and Twist in breast cancer. 240 In addition, treatment with the novel and effective PI3K inhibitor serabelisib is reported to suppress the EMT process via PI3K/Akt/E‐cadherin signaling pathway, thereby inhibiting the migration of hepatoma cells.…”

Section: Therapeutic Strategies Targeting Empmentioning

confidence: 99%

Epithelial–mesenchymal plasticity in cancer: signaling pathways and therapeutic targets

Wang,

Xue,

Pang

et al. 2024

MedComm

View full text Add to dashboard Cite

Currently, cancer is still a leading cause of human death globally. Tumor deterioration comprises multiple events including metastasis, therapeutic resistance and immune evasion, all of which are tightly related to the phenotypic plasticity especially epithelial–mesenchymal plasticity (EMP). Tumor cells with EMP are manifest in three states as epithelial–mesenchymal transition (EMT), partial EMT, and mesenchymal–epithelial transition, which orchestrate the phenotypic switch and heterogeneity of tumor cells via transcriptional regulation and a series of signaling pathways, including transforming growth factor‐β, Wnt/β‐catenin, and Notch. However, due to the complicated nature of EMP, the diverse process of EMP is still not fully understood. In this review, we systematically conclude the biological background, regulating mechanisms of EMP as well as the role of EMP in therapy response. We also summarize a range of small molecule inhibitors, immune‐related therapeutic approaches, and combination therapies that have been developed to target EMP for the outstanding role of EMP‐driven tumor deterioration. Additionally, we explore the potential technique for EMP‐based tumor mechanistic investigation and therapeutic research, which may burst vigorous prospects. Overall, we elucidate the multifaceted aspects of EMP in tumor progression and suggest a promising direction of cancer treatment based on targeting EMP.

show abstract

Section: Therapeutic Strategies Targeting Empmentioning

confidence: 99%

Epithelial–mesenchymal plasticity in cancer: signaling pathways and therapeutic targets

Wang,

Xue,

Pang

et al. 2024

MedComm

View full text Add to dashboard Cite

show abstract

Innovative drug delivery strategies for targeting glioblastoma: overcoming the challenges of the tumor microenvironment

Khot,

Krishnaveni,

Gharat

et al. 2024

Expert Opinion on Drug Delivery

View full text Add to dashboard Cite

Prospecting Pharmacologically Active Biocompounds from the Amazon Rainforest: In Vitro Approaches, Mechanisms of Action Based on Chemical Structure, and Perspectives on Human Therapeutic Use

de Almada-Vilhena,

dos Santos,

Machado

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

The Amazon rainforest is an important reservoir of biodiversity, offering vast potential for the discovery of new bioactive compounds from plants. In vitro studies allow for the investigation of biological processes and interventions in a controlled manner, making them fundamental for pharmacological and biotechnological research. These approaches are faster and less costly than in vivo studies, providing standardized conditions that enhance the reproducibility and precision of data. However, in vitro methods have limitations, including the inability to fully replicate the complexity of a living organism and the absence of a complete physiological context. Translating results to in vivo models is not always straightforward, due to differences in pharmacokinetics and biological interactions. In this context, the aim of this literature review is to assess the advantages and disadvantages of in vitro approaches in the search for new drugs from the Amazon, identifying the challenges and limitations associated with these methods and comparing them with in vivo testing. Thus, bioprospecting in the Amazon involves evaluating plant extracts through bioassays to investigate pharmacological, antimicrobial, and anticancer activities. Phenolic compounds and terpenes are frequently identified as the main bioactive agents, exhibiting antioxidant, anti-inflammatory, and antineoplastic activities. Chemical characterization, molecular modifications, and the development of delivery systems, such as nanoparticles, are highlighted to improve therapeutic efficacy. Therefore, the Amazon rainforest offers great potential for the discovery of new drugs; however, significant challenges, such as the standardization of extraction methods and the need for in vivo studies and clinical trials, must be overcome for these compounds to become viable medications.

show abstract

Ursolic acid inhibits glioblastoma through suppressing TGFβ-mediated epithelial-mesenchymal transition (EMT) and angiogenesis

Cited by 3 publications

References 39 publications

Epithelial–mesenchymal plasticity in cancer: signaling pathways and therapeutic targets

Epithelial–mesenchymal plasticity in cancer: signaling pathways and therapeutic targets

Innovative drug delivery strategies for targeting glioblastoma: overcoming the challenges of the tumor microenvironment

Prospecting Pharmacologically Active Biocompounds from the Amazon Rainforest: In Vitro Approaches, Mechanisms of Action Based on Chemical Structure, and Perspectives on Human Therapeutic Use

Contact Info

Product

Resources

About